Intellia Therapeutics (NTLA) Leases (2019 - 2025)
Historic Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $117.9 million.
- Intellia Therapeutics' Leases rose 1749.41% to $117.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.9 million, marking a year-over-year increase of 1749.41%. This contributed to the annual value of $219.3 million for FY2024, which is 9006.89% up from last year.
- Per Intellia Therapeutics' latest filing, its Leases stood at $117.9 million for Q3 2025, which was up 1749.41% from $129.0 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Leases ranged from a high of $219.3 million in Q4 2024 and a low of $1.4 million during Q2 2021
- Moreover, its 5-year median value for Leases was $110.4 million (2024), whereas its average is $100.9 million.
- Its Leases has fluctuated over the past 5 years, first plummeted by 9403.47% in 2021, then surged by 516964.29% in 2022.
- Over the past 5 years, Intellia Therapeutics' Leases (Quarter) stood at $79.1 million in 2021, then soared by 68.15% to $133.1 million in 2022, then fell by 13.3% to $115.4 million in 2023, then soared by 90.07% to $219.3 million in 2024, then crashed by 46.24% to $117.9 million in 2025.
- Its last three reported values are $117.9 million in Q3 2025, $129.0 million for Q2 2025, and $138.0 million during Q1 2025.